Combination therapy aims to wipe out High-Risk prostate cancer before surgery
NCT ID NCT07677566
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial investigates whether combining a targeted radioactive drug (177Lu-PSMA-617) with a hormone therapy (darolutamide) before surgery can improve outcomes for men with high-risk localized prostate cancer. Participants receive two doses of the radioactive drug and daily hormone pills for 12 weeks, then undergo prostate removal. The study measures how many patients have no detectable cancer or only minimal residual disease in the removed tissue, and tracks side effects and sexual function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (targeted radiation) and darolutamide (hormone therapy)
What this could lead to
If successful, this approach could become a standard pre-surgery treatment to eliminate more cancer cells and lower the chance of recurrence in high-risk prostate cancer.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. The combination may cause side effects like fatigue, dry mouth, or blood cell changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••